FDA approved seven next-generation gram-negative antibiotics between 2014 and 2019. Yet a study published in the May 2024 issue of the Annals of Internal Medicine found that between 2016 and 2021, clinicians in 619 U.S. hospitals treated more than 40% of patients who had highly antibiotic-resistant pathogens exclusively with older, generic agents. Furthermore, most of these older agents had known suboptimal safety and/or efficacy.
Terri D’Arrigo